The 7th European Stroke Conference (ESOC), held online from 1 - 3 September 2021, is the leading forum in Europe for advances in research and clinical care of patients with cerebrovascular disease and a world-class platform for release of major clinical trial data.
Two academic studies conducted on Sanbexin® (edaravone and dexborneol concentrated solution for injection), Simcere's new category 1 drug for the treatment of acute ischemic stroke, was included in ESOC’s abstract. Key research data was released during the conference.
Abstract Number: 877
Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Large Artery Atherosclerosis Stroke Subtypes: A Secondary Analysis of the TASTE Trial
First author: Jie Xu
Communication author: Yongjun Wang (Beijing Tiantan Hospital, Capital Medical University)
Results: Edaravone dexborneol group showed largely higher proportion of mRS score ≤1 on D90 than edaravone group (59.41% versus 51.45%; OR 1.38 [95% CI, 1.02–1.87]; P=0.036). Patients with edaravone dexborneol treatment had higher odds of mRS score on D90 than edaravone group ([OR 1.35 [95% CI, 1.03-1.77]; P=0.031). Significant differences occurred between two groups in the NIHSS score from baseline to D14 ([95% CI, -0.92 to -0.01]; P＜0.01). The safety outcome indicated that the two groups had similar incidences of AEs.
This analysis demonstrated that Edaravone dexborneol showed better functional outcomes than edaravone in LAA stroke, which may further support the clinical application of Edaravone dexborneol for AIS treatment.
Abstract Number: 1264
Effects of Edaravone-Dexborneol on the global cerebral ischemia strokein rats
Fisrt author & Communication author: Guanhua Du (Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College)
Results: Edaravone-dexborneol could decrease the free radical and oxidizing agent levels significantly in a dose-dependent manner. In addition, mitochondrial oxidative phosphorylation function was also boosted by Edaravone-dexborneol. A significant increase of the learning and memory function was observed in the rat model.
Sanbexin® is the only innovative drug for stroke approved over the past five years worldwide. Research data from phase III clinical research "TASTE" was published in STROKE earlier this year, which showed positive treatment effect of Sanbexin®.
This result attracted widespread attention from the academic community in China and abroad. Since its launch one year ago, the product has benefited nearly 200,000 stroke patients in China, and has been included in China’s first edition of the Chinese Expert Consensus on the Clinical Evaluation and Treatment of Penumbra in Acute Cerebral Infarction Ischemic.
The study data released at ESOC 2021 are from further exploration of subgroup clinical data and mechanism research of Sanbexin® carried out by Chinese clinical and pharmaceutical scholars. This provides high-quality evidence for broader clinical application of Sanbexin® in the future, and also allows the international academic community to further understand this innovative stroke management drug with its dual protection mechanisms, independently developed by China.